Immix Biopharma, Inc. (NASDAQ:IMMX) Receives $19.50 Consensus Price Target from Analysts

Immix Biopharma, Inc. (NASDAQ:IMMX) has received an average rating of “Moderate Buy” from the nine analysts that are presently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and seven have given a buy rating to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $20.6667.

A number of research analysts have recently weighed in on the company. Citizens Jmp reissued a “market outperform” rating and issued a $23.00 price objective on shares of Immix Biopharma in a report on Friday, March 27th. Bank of America began coverage on Immix Biopharma in a report on Thursday, June 18th. They set a “buy” rating and a $27.00 target price for the company. Wall Street Zen lowered Immix Biopharma from a “hold” rating to a “sell” rating in a research report on Sunday, March 15th. Citigroup started coverage on shares of Immix Biopharma in a report on Thursday, June 18th. They issued a “buy” rating on the stock. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Immix Biopharma in a research report on Tuesday, April 21st.

Immix Biopharma Trading Up 5.4%

NASDAQ:IMMX opened at $9.91 on Wednesday. Immix Biopharma has a 12 month low of $1.94 and a 12 month high of $11.61. The firm has a fifty day simple moving average of $9.21 and a 200-day simple moving average of $7.86. The company has a market capitalization of $539.20 million, a P/E ratio of -10.77 and a beta of 0.10.

Immix Biopharma (NASDAQ:IMMX) last released its earnings results on Thursday, May 7th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.01. Equities analysts forecast that Immix Biopharma will post -0.69 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Bank of America Corp DE boosted its holdings in Immix Biopharma by 256,968.8% in the first quarter. Bank of America Corp DE now owns 41,131 shares of the company’s stock valued at $375,000 after purchasing an additional 41,115 shares during the last quarter. Janus Henderson Group PLC grew its position in Immix Biopharma by 22.5% during the 1st quarter. Janus Henderson Group PLC now owns 4,802,002 shares of the company’s stock worth $43,698,000 after purchasing an additional 880,434 shares during the period. The Manufacturers Life Insurance Company purchased a new position in shares of Immix Biopharma during the 1st quarter valued at about $264,000. Sei Investments Co. lifted its holdings in shares of Immix Biopharma by 100.0% in the 1st quarter. Sei Investments Co. now owns 147,140 shares of the company’s stock valued at $1,340,000 after buying an additional 73,570 shares during the period. Finally, LGT Fund Management Co Ltd. lifted its holdings in shares of Immix Biopharma by 233.3% in the 1st quarter. LGT Fund Management Co Ltd. now owns 416,594 shares of the company’s stock valued at $3,795,000 after buying an additional 291,594 shares during the period. 11.26% of the stock is currently owned by institutional investors and hedge funds.

About Immix Biopharma

Immix Biopharma (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company’s approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.

The company’s lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.